कंपनी का अवलोकन
Neumora Therapeutics, Inc. operates as a clinical-stage biopharmaceutical entity focused on the development of therapeutic interventions for brain diseases, neuropsychiatric disorders, and neurodegenerative conditions within the United States market. The company functions within the broader Healthcare sector, specifically targeting the specialized Biotechnology industry, which implies a focus on innovative drug discovery and clinical trial execution rather than commercialized product sales. As of the latest available data, the company holds a market capitalization of $364.08M, though its annual revenue and total employee count are currently unlisted or negligible, indicating a pre-revenue or early-stage operational model. This specific market capitalization relative to the absence of reported revenue suggests the entity is valued primarily on potential future clinical outcomes and intellectual property rather than current cash generation, positioning it as a high-risk, high-potential venture typical of clinical-stage development firms.
वित्तीय स्वास्थ्य
The financial statements reveal a Net Income of $-236,928,000 and an EBITDA of $-235,948,000, while Revenue for the trailing twelve months is not available, highlighting a significant disparity where operating expenses and research costs far exceed any current income generation. This substantial gap between revenue and net income indicates that the company's cost structure is entirely driven by heavy investment in clinical operations and development activities, resulting in a negative bottom line typical of entities in the early phases of the drug development lifecycle. The Free Cash Flow stands at $-115,712,376, which signifies a continuous burn rate that limits immediate financial flexibility and necessitates reliance on external capital sources or existing cash reserves to sustain operations. Regarding profitability metrics, the Gross Margin, Operating Margin, and Profit Margin are all recorded at 0.0%, reflecting that the company has not yet achieved commercial sales volumes necessary to generate a positive margin on revenue. In terms of liquidity management, the company maintains Cash reserves of $182.53M against Total Debt of $55.01M, suggesting a net cash position, yet the Debt to Equity ratio of 52.96 presents a complex picture of leverage relative to equity. The Current Ratio is reported at 5.87, indicating a robust short-term liquidity position where current assets significantly exceed current liabilities, providing a buffer for operational continuity despite the cash burn. Furthermore, the Return on Equity is -121.2% and the Return on Assets is -58.1%, metrics that reveal that management is currently utilizing shareholder capital and assets to generate negative returns due to the accumulation of losses during the development stage.
मूल्यांकन आकलन
The valuation metrics present a challenging picture, with a Forward P/E of -2.16 and a Trailing P/E (TTM) marked as N/A due to the lack of positive earnings, implying that traditional earnings-based valuation models are not applicable at this stage. The Price to Book ratio is 3.36, which indicates that the market is pricing the company at a significant premium over its book value, a common phenomenon for biotechnology firms where future clinical success potential outweighs current asset valuation. Alternative valuation measures such as the Price to Sales ratio (N/A) and EV/EBITDA (-1.00) further illustrate the difficulty in applying standard financial multiples to a company with no revenue and negative earnings, suggesting value is derived from intangible assets and pipeline potential rather than financial performance. The stock price has fluctuated between a 52-Week High of $3.65 and a 52-Week Low of $0.61, with the current trading position situated within this range, reflecting the high volatility associated with clinical-stage biotech stocks. The Beta of 3.12 confirms that the stock exhibits substantial price volatility relative to the broader market, moving with significantly higher intensity than the overall market index.
Growth & Income
The company reports N/A for both Revenue Growth (YoY) and Earnings Growth (YoY), which precludes any analysis of growth rates as the business has not yet transitioned to a revenue-generating phase. Since the company does not distribute dividends, the Dividend Yield is N/A and the Payout Ratio is 0.0%, indicating that the company retains all available earnings, though in this case, those earnings are negative, to reinvest into research and development efforts rather than shareholder payouts. This reinvestment strategy is standard for clinical-stage entities, where capital is directed toward advancing navacaprant (NMRA-140) and other therapeutic candidates through clinical trials to achieve market approval. Consequently, the overall growth and income profile is characterized by a complete reliance on future clinical milestones for potential revenue expansion, with no current contribution to shareholder income through dividends or earnings growth.